PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA for orphan drug designation as it works to further study the uses of ketamine. The latest filing pertains to the use of ketamine to treat Lou Gehrig’s disease, which is formally known as ALS, or amyotrophic lateral sclerosis.

Lou Gehrig’s disease is a neuromuscular disease, which currently has a life expectancy of just two to six years after initial diagnosis. The disease effectively causes upper and lower motor neurons to die, causing the brain to lose function of muscle movement. As the disease progresses patients lose voluntary muscle action, causing the inability to speak, eat, move and breathe. There is currently no cure for the disease.

Initial research conducted on ketamine has indicated that it has the potential to increase life expectancy of those impacted by the disease, slowing the progressive loss of muscle. Preclinical work has demonstrated that the compound preserves muscle function in advancing ALS, and improves life expectancy when administered early in the stages of muscles decline.

“Ketamine has tremendous potential for not only mental illness and pain disorders but also for neurodegenerative diseases such as ALS.  Our FDA orphan drug application for ketamine to treat this life-threatening disease complements our patent portfolio that aims to protect the proposed method of use and dosage claims of ketamine for ALS.  Although patent protection or market exclusivity could last beyond 2040, our intention to seek orphan drug designation is to leverage the expedited regulatory and clinical development incentives offered by the FDA for repurposed drugs in treating rare diseases.”

Fabio Chianelli, Chief Executive Officer of PharmaTher

PharmaTher Holdings last traded at $0.40 on the CSE.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketabet

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the...

Tuesday, June 15, 2021, 08:14:25 AM

Pharmather Appoints Dr Alberto J Espay As Scientific Advisor

Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific...

Wednesday, November 11, 2020, 08:29:13 AM

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM

PharmaTher Partners With TSRL For Microneedle Patch Development

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The...

Tuesday, June 1, 2021, 08:21:51 AM